Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Triple Negative Breast Cancer
Clinical trial register · China

Triple Negative Breast Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19224 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:17 UTC
19224
Studies in scope
all four open statuses
11811
Recruiting now
open to new participants
2030
Lead sponsors
across recruiting studies
Top sites
Shanghai 15 Guangzhou 14 Beijing 13 Harbin 6 Fuzhou 5
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University10 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University3 Shanghai Junshi Bioscience Co., Ltd.2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.2 Hebei Medical University Fourth Hospital2 Sichuan Baili Pharmaceutical Co., Ltd.2 RenJi Hospital1 Peking University Cancer Hospital & Institute1 Shu Wang1 Fujian Cancer Hospital1 Mabwell (Shanghai) Bioscience Co., Ltd.1 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.1 First Affiliated Hospital of Zhejiang University1 Beijing Biotech1 Liu Shu1 Henan Cancer Hospital1 Sun Yat-sen University1 Jiangsu Alphamab Biopharmaceuticals Co., Ltd1 Zhejiang Cancer Hospital1 Sun Yat-Sen University Cancer Center1 West China Hospital1 Shengjing Hospital1 AstraZeneca1 Tianjin Medical University Cancer Institute and Hospital1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1 Gilead Sciences1 Nanjing Leads Biolabs Co.,Ltd1 Chinese Academy of Medical Sciences1 Guangdong Provincial People's Hospital1 The First Affiliated Hospital of Bengbu Medical University1 OBI Pharma, Inc1 Peking University People's Hospital1 Zhenzhen Liu1 Suzhou Suncadia Biopharmaceuticals Co., Ltd.1
Site location
Shanghai15 Guangzhou14 Beijing13 Harbin6 Fuzhou5 Zhengzhou5 Wuhan4 Nanjing4 Chongqing4 Hangzhou3 Shijiazhuang3 Guiyang3 Chengdu3 Shenyang3 Changchun3 Changsha3 Hefei2 Baoding2 Bengbu2 Ningde1 Quanzhou1 Sanming1 Shenzhen1 Zhangzhou1 Guandong1 Lanzhou1 Dalian1 Tianjin1 Deyang1 Nanning1 Guangdong1 Nantong1 Yangzhou1 Yichang1 Yongzhou1
All 35 locations
Target enrolment
to

Triple Negative Breast Cancer trials in China

49 of 19224 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Fudan University
Phase 2
46
Shanghai
2027-01-01
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
184
Beijing, Fuzhou, Lanzhou, Guangzhou, Guiyang, Baoding, Harbin, Zhengzhou
2026-10-22
Recruiting
Fujian Cancer Hospital
Observational
120
Fuzhou, Ningde, Quanzhou, Sanming
2026-10-08
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
1,000
Beijing
2026-09-02
Recruiting
Liu Shu
Phase 1/2
30
Guiyang
2026-07-30
Recruiting
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3
364
Guangzhou
2026-03-17
Recruiting
RenJi Hospital
Phase 2
46
Shanghai
2026-03-01
Recruiting
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
NCT07510802Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-02-02
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
220
Guangzhou, Harbin, Zhengzhou, Nanjing, Changchun, Shenyang
2026-01-27
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
416
Guangzhou
2025-12-31
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
80
Hefei, Beijing, Guangzhou, Baoding, Harbin, Zhangzhou, Wuhan, Nanjing
2025-09-17
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
59
Tianjin
2025-08-15
Recruiting
Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
NCT07705438Triple Negative Breast Cancer, Immune Checkpoint Inhibitor, Granzyme B PET/CT
Fudan University
Observational
30
Shanghai
2025-05-28
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
246
Guangzhou, Guiyang, Wuhan, Yichang, Changsha, Yongzhou, Shanghai
2025-02-21
Recruiting
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
NCT06817525Triple-negative Breast Cancer
Henan Cancer Hospital
Phase 2
64
Zhengzhou
2024-11-06
Recruiting
First Affiliated Hospital of Zhejiang University
Not applicable
29
Hangzhou
2024-10-10
Recruiting
Zhejiang Cancer Hospital
Phase 2
20
Hangzhou
2024-08-20
Active, closed
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 3
350
Shanghai
2024-08-09
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
52
Shanghai
2024-08-02
Recruiting
Guangdong Provincial People's Hospital
Phase 3
310
Guangzhou
2024-08-01
Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2
160
Shanghai
2024-07-26
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
418
Shanghai
2024-06-21
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
27
Wuhan
2024-05-01
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
537
Shanghai
2024-02-28
Not yet open
Shengjing Hospital
Phase 2
128
Shenyang
2024-02-10
Recruiting
Fudan University
Phase 3
764
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-20
Active, closed
Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
NCT07018427Breast Neoplasms, Triple Negative Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Breast Cancer
DrugSacituzumab Govitecan
Peking University Cancer Hospital & Institute
Observational
70
Beijing
2023-05-01
Recruiting
Fudan University
Phase 3
134
Shanghai
2023-04-25
Recruiting
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
NCT05749588Triple-negative Breast Cancer
DrugCamrelizumab
Fudan University
Phase 2
120
Shanghai
2023-03-30
Recruiting
Fudan University
Phase 3
223
Shanghai
2023-03-17
Recruiting
Zhenzhen Liu
Phase 2
369
Zhengzhou
2022-12-20
Recruiting
West China Hospital
Phase 2
35
Chengdu
2022-11-01
Active, closed
Gilead Sciences
Phase 3
623
Beijing, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou, Harbin
2022-07-20
Active, closed
AstraZeneca
Phase 1/2
119
Beijing, Bengbu, Changchun, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-07-11
Recruiting
Fudan University
Phase 2
90
Shanghai
2022-06-30
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
254
Beijing, Nanjing
2022-06-10
Recruiting
The First Affiliated Hospital of Bengbu Medical University
Phase 2
128
Bengbu
2022-01-14
Active, closed
Sun Yat-sen University
Phase 2
51
Guangzhou
2022-01-11
Recruiting
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
NCT04790305Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast
DrugHuaier
Fudan University
Phase 4
1,072
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2021-06-18
Recruiting
Sun Yat-Sen University Cancer Center
Phase 3
228
Guangzhou
2021-04-20
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
460
Guandong
2020-08-03
Active, closed
Fudan University
Phase 3
808
Shanghai
2020-03-05
Recruiting
Chinese Academy of Medical Sciences
Phase 2
286
Beijing
2020-02-01
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
414
Shijiazhuang
2019-11-20
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
520
Shijiazhuang
2019-11-20
Recruiting
Shu Wang
Observational
1,166
Beijing
2019-01-01
Recruiting
Peking University People's Hospital
Observational
380
Beijing
2019-01-01
Active, closed
OBI Pharma, Inc
Phase 3
575
Beijing, Guangzhou, Nanning, Harbin, Wuhan, Changsha, Nanjing, Changchun
2018-12-05
Active, closed
Fudan University
Phase 2/3
503
Shanghai
2016-01
Rows per page Showing 1–49 of 49
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 November 2026. https://priyalifescience.com/clinical-trials-china/condition/triple-negative-breast-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,224 studies in total at the last sync on 11 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 49 of those studies listing the condition Triple Negative Breast Cancer.

How many Triple Negative Breast Cancer trials are recruiting in China?

35 of the 49 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:17 UTC sync. A further 3 have not yet opened recruitment, 11 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Triple Negative Breast Cancer), 49 studies
PhaseStudiesRecruitingShare
Phase 2211842.9%
Phase 315830.6%
Observational5410.2%
Phase 1/25310.2%
Not applicable112%
Phase 2/3102%
Phase 4112%

Most active sponsors

Lead sponsors with the most studies (Triple Negative Breast Cancer)
Lead sponsorStudiesRecruiting
Fudan University107
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University33
Hebei Medical University Fourth Hospital22
Shanghai Junshi Bioscience Co., Ltd.22
Sichuan Baili Pharmaceutical Co., Ltd.21
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.20
AstraZeneca10
Beijing Biotech11
Chinese Academy of Medical Sciences11
First Affiliated Hospital of Zhejiang University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.